BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21541704)

  • 21. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment.
    Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V
    J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity.
    Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura A; Lawrence J; Berstein L; Yue W
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S61-73. PubMed ID: 16113100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction between IGF-IR and ER induced by E2 and IGF-I.
    Yu Z; Gao W; Jiang E; Lu F; Zhang L; Shi Z; Wang X; Chen L; Lv T
    PLoS One; 2013; 8(5):e62642. PubMed ID: 23704881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autocrine regulation of cell proliferation by estrogen receptor-alpha in estrogen receptor-alpha-positive breast cancer cell lines.
    Tan H; Zhong Y; Pan Z
    BMC Cancer; 2009 Jan; 9():31. PubMed ID: 19171042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells.
    Fan P; Agboke FA; McDaniel RE; Sweeney EE; Zou X; Creswell K; Jordan VC
    Eur J Cancer; 2014 Jan; 50(2):457-68. PubMed ID: 24183378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Favorable outcome associated with an IGF-1 ligand signature in breast cancer.
    Mu L; Tuck D; Katsaros D; Lu L; Schulz V; Perincheri S; Menato G; Scarampi L; Harris L; Yu H
    Breast Cancer Res Treat; 2012 May; 133(1):321-31. PubMed ID: 22297468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways.
    Rao X; Di Leva G; Li M; Fang F; Devlin C; Hartman-Frey C; Burow ME; Ivan M; Croce CM; Nephew KP
    Oncogene; 2011 Mar; 30(9):1082-97. PubMed ID: 21057537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Binding of anterior gradient 2 and estrogen receptor-α: Dual critical roles in enhancing fulvestrant resistance and IGF-1-induced tumorigenesis of breast cancer.
    Li Z; Zhu Q; Chen H; Hu L; Negi H; Zheng Y; Ahmed Y; Wu Z; Li D
    Cancer Lett; 2016 Jul; 377(1):32-43. PubMed ID: 27063095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen receptor-dependent regulation of CYP2B6 in human breast cancer cells.
    Lo R; Burgoon L; Macpherson L; Ahmed S; Matthews J
    Biochim Biophys Acta; 2010; 1799(5-6):469-79. PubMed ID: 20079471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aryl hydrocarbon receptor modulation of estrogen receptor α-mediated gene regulation by a multimeric chromatin complex involving the two receptors and the coregulator RIP140.
    Madak-Erdogan Z; Katzenellenbogen BS
    Toxicol Sci; 2012 Feb; 125(2):401-11. PubMed ID: 22071320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development.
    Thaler S; Schmidt M; Schad A; Sleeman JP
    Oncogene; 2012 Nov; 31(47):4912-22. PubMed ID: 22266866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The estrogen receptor alpha:insulin receptor substrate 1 complex in breast cancer: structure-function relationships.
    Sisci D; Morelli C; Cascio S; Lanzino M; Garofalo C; Reiss K; Garcia M; Russo A; Andò S; Surmacz E
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi81-5. PubMed ID: 17591841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components.
    Dupont J; Karas M; LeRoith D
    J Biol Chem; 2000 Nov; 275(46):35893-901. PubMed ID: 10967123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen receptor α dependent regulation of estrogen related receptor β and its role in cell cycle in breast cancer.
    Madhu Krishna B; Chaudhary S; Mishra DR; Naik SK; Suklabaidya S; Adhya AK; Mishra SK
    BMC Cancer; 2018 May; 18(1):607. PubMed ID: 29843638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.
    Law JH; Habibi G; Hu K; Masoudi H; Wang MY; Stratford AL; Park E; Gee JM; Finlay P; Jones HE; Nicholson RI; Carboni J; Gottardis M; Pollak M; Dunn SE
    Cancer Res; 2008 Dec; 68(24):10238-46. PubMed ID: 19074892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpressed IGF-I receptors reduce estrogen growth requirements, enhance survival, and promote E-cadherin-mediated cell-cell adhesion in human breast cancer cells.
    Guvakova MA; Surmacz E
    Exp Cell Res; 1997 Feb; 231(1):149-62. PubMed ID: 9056422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer.
    Schnarr B; Strunz K; Ohsam J; Benner A; Wacker J; Mayer D
    Int J Cancer; 2000 Nov; 89(6):506-13. PubMed ID: 11102895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
    Mishra AK; Abrahamsson A; Dabrosin C
    Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells.
    Li Z; Levine KM; Bahreini A; Wang P; Chu D; Park BH; Oesterreich S; Lee AV
    Endocrinology; 2018 Jan; 159(1):285-296. PubMed ID: 29029116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The WT1 Wilms' tumor suppressor gene product interacts with estrogen receptor-alpha and regulates IGF-I receptor gene transcription in breast cancer cells.
    Reizner N; Maor S; Sarfstein R; Abramovitch S; Welshons WV; Curran EM; Lee AV; Werner H
    J Mol Endocrinol; 2005 Aug; 35(1):135-44. PubMed ID: 16087727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.